You are here: Industry Insights > CLL

News List

Oncternal gets FDA orphan drug designations for cirmtuzumab to treat MCL and CLL pharmaceutical-business-review
July 06, 2020
Oncternal Therapeutics announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukaemia ...
Regulators expand review time for Novartis' MS drug pharmatimes
June 05, 2020
US regulators are extending the review time for Novartis' MS therapy ofatumumab.
Shilpa Medicare IBRUSHIL for treatment of leukaemia expresspharma
May 29, 2020
Earlier it had launched Lenvatinib ‘LENSHIL and Dasatinib ‘DASASHIL’ in the India market.
AbbVie Receives EC Approval of VENCLYXTO Regimen for Lymphocytic Leukemia americanpharmaceuticalreview
March 16, 2020
AbbVie announced the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with obinutuzumab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) ...
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017 drugs
December 27, 2019
For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL pharmaceutical-business-review
December 11, 2019
AstraZeneca presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or ...
AstraZeneca announces breakthrough therapy status for Calquence in CLL pharmaceutical-technology
August 15, 2019
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL).
Drug Duo May Be an Advance Against a Common Leukemia drugs
August 01, 2019
A two-drug combo helps patients with a common form of leukemia survive longer than the current standard of care, a new clinical trial finds.
FDA Approves Roche’s Venclexta for CLL contractpharma
June 12, 2019
Venclexta combined with Gazyva is an approved chemotherapy-free option for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions drugs
June 05, 2019
Combo Regimen Effective in CLL With Coexisting Conditions.

Previous page 1 2 3 4 Next page